RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · IEX Real-Time Price · USD
0.362
-0.004 (-1.09%)
At close: Jul 2, 2024, 3:58 PM
0.360
-0.002 (-0.55%)
After-hours: Jul 2, 2024, 7:54 PM EDT
RedHill Biopharma Revenue
In the year 2023, RedHill Biopharma had annual revenue of $6.53M, a decrease of -89.43%.
Revenue (ttm)
$6.53M
Revenue Growth
-90.81%
P/S Ratio
1.77
Revenue / Employee
$123,208
Employees
53
Market Cap
11.54M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.53M | -55.27M | -89.43% |
Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
Dec 31, 2019 | 6.29M | -2.07M | -24.75% |
Dec 31, 2018 | 8.36M | 4.35M | 108.63% |
Dec 31, 2017 | 4.01M | 3.91M | 3,867.33% |
Dec 31, 2016 | 101.00K | 98.00K | 3,266.67% |
Dec 31, 2015 | 3.00K | -7.01M | -99.96% |
Dec 31, 2014 | 7.01M | 7.00M | 58,350.00% |
Dec 30, 2013 | 12.00K | -4.00K | -25.00% |
Dec 31, 2012 | 16.00K | -7.00K | -30.43% |
Dec 31, 2011 | 23.00K | - | - |
Dec 31, 2010 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Centogene | 53.93M |
Elevai Labs | 2.18M |
Addex Therapeutics | 1.57M |
Traws Pharma | 226.00K |
Organovo Holdings | 109.00K |
Cardio Diagnostics Holdings | 32.99K |
RDHL News
- 4 weeks ago - RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 - PRNewsWire
- 2 months ago - RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - PRNewsWire
- 2 months ago - RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study - PRNewsWire
- 3 months ago - RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights - PRNewsWire
- 3 months ago - RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price - PRNewsWire
- 4 months ago - RedHill Announces New USPTO Patent Covering Talicia® Through 2034 - PRNewsWire
- 4 months ago - RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - PRNewsWire
- 4 months ago - RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication - PRNewsWire